IDH2 and melanoma: In mouse models of leukemia and melanoma, IDH mutants accelerated cell cycle transition by activation of the MAPK/ERK pathway and repression of tumor suppressors CDKN2A and CDKN2B (Chaturvedi et al., 2013; Shibata et al., 2011).